Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.

Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

NanoScope Technologies was founded in 2009 with an objective to develop new methods and devices for scientific, industrial and biomedical applications. Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. These have already generated interest from several clinicians, industries and leaders. We strive to translate the technology to market and bedside.

Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. It involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Innovo Mimetics operates in the field of personalized medicine specializing in anti-cancer therapy efficacy assays in the chick egg tumor xenograft model. This model is based on the ability of a fertilized chick egg to engraft and nourish foreign and cancer cells placed in the egg. Its proprietary assay system allows rapid and low-cost evaluation of chemical, biological, and cell therapies.

Orbis Health Solutions eradicates cancer and immune-mediated diseases. The company offers both internal research and development and partnerships with business and academic partners. The company creates the tumor lysate, or particle only vaccine, an autologous or personalized therapeutic cancer shot meant to arouse the immune system to identify tumor cells and combat a patient's particular cancer.

Suzhou Relai Biotechnology Co., Ltd., established on 2013-06-20, Business scope includes biomedical technology,Development of new material technology,Consulting and Services;Medical device research and development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Production of Class II Medical Devices;Life beauty service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Traditional Chinese Medicine Health Care Services(non-medical);Human stem cell technology development and application;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)